![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png)
That's $450.00, as in I can pull that out of an ATM pretty much any time. Not $450 million. A little under five hundred bucks, and they lost their lock on their second largest market.
The Slashdot summary says it best:
"Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking more time to decide whether to continue protecting the patent.
When the 2019 fee came due at $450 with late penalties, Novo never paid despite having a one-year grace period. Canadian patent authorities confirmed the patent "cannot be revived" once lapsed. The oversight is particularly costly given Canada represents the world's second-largest semaglutide market, worth billions annually. Generic drugmaker Sandoz plans to launch a competing version in early 2026, while Novo's U.S. patent protection extends until at least 2032.
WOW. That's certainly going to tarnish some board member's CV. But it's going to make a bunch of Canadian's a lot thinner!
https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake
https://science.slashdot.org/story/25/06/16/1438211/novo-nordisk-loses-canadian-patent-protection-for-blockbuster-diabetes-drug-over-unpaid-450-fee
The Slashdot summary says it best:
"Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking more time to decide whether to continue protecting the patent.
When the 2019 fee came due at $450 with late penalties, Novo never paid despite having a one-year grace period. Canadian patent authorities confirmed the patent "cannot be revived" once lapsed. The oversight is particularly costly given Canada represents the world's second-largest semaglutide market, worth billions annually. Generic drugmaker Sandoz plans to launch a competing version in early 2026, while Novo's U.S. patent protection extends until at least 2032.
WOW. That's certainly going to tarnish some board member's CV. But it's going to make a bunch of Canadian's a lot thinner!
https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake
https://science.slashdot.org/story/25/06/16/1438211/novo-nordisk-loses-canadian-patent-protection-for-blockbuster-diabetes-drug-over-unpaid-450-fee
no subject
Date: 2025-06-16 04:41 pm (UTC)On a separate note, can't comprehend how Canada can be the second largest market for that shit. We aren't that fat! Or maybe it's my Quebec prospective, idk
no subject
Date: 2025-06-16 06:24 pm (UTC)Oh, yeah, we can have metabolic troubles of our own. Not simply over-eating either, but accumulating body fat regardless of our choices and intentions.
no subject
Date: 2025-06-16 06:37 pm (UTC)There's also the diabetes origin of the drug.
no subject
Date: 2025-06-16 06:35 pm (UTC)It's possible that the diabetic drug side of it makes it the second largest market, I don't know.
no subject
Date: 2025-06-16 04:52 pm (UTC)no subject
Date: 2025-06-16 06:36 pm (UTC)I wonder if they'll jack up the price in the USA to make up the diff. It wouldn't be out of character.
no subject
Date: 2025-06-16 08:06 pm (UTC)no subject
Date: 2025-06-16 08:10 pm (UTC)Someone really, really screwed up!
no subject
Date: 2025-06-17 04:01 am (UTC)Somebody's head is going to roll. :o :o :o
Hugs, Jon
no subject
Date: 2025-06-17 04:41 am (UTC)Most definitely!
no subject
Date: 2025-06-17 05:09 am (UTC)They will pick a peon. :o
no subject
Date: 2025-06-17 05:21 am (UTC)Yeah, sacrifice someone who doesn't earn 6-7 digits.
no subject
Date: 2025-06-17 05:41 am (UTC)